Arvind Kumar1, Usha Singh2
BACKGROUND
Giant Cell Tumour (GCT) of bone, one of the commonest bone tumours is usually benign are locally aggressive and may occasionally undergo malignant transformation. The surgeon needs to strike a balance during treatment between reducing the incidence of local recurrence while preserving maximum function.
The aim of the study is to clarify the clinicopathological correlation of tumour and its relevance in treatment and prognosis.
MATERIALS AND METHODS
This study is retrospective analysis of 16 patients of histopathologically-proven giant cell tumours of bone between 2014 to 2016 in private hospital of Patna. Information regarding patient’s demography, tumour location, treatment and outcome was recorded and analysed.
RESULTS
Out of 16 patients of GCT, 8 (50%) patients belong to age range of 30-39 years. Females were affected more than males. Male-to-female ratio were 1:1.4. Majority of GCT were of grade I (68.7%), followed by grade II (25%) and grade III (6.2%). Most common sites of GCT were femur lower end (25%) and tibia upper end (25%), followed by radius lower end (12.5%). Other sites were humerus upper end (6.2%), clavicle (6.2%), fibula upper end (6.2%), ulna lower end (6.2%), metatarsal (6.2%) and patella (6.2%). Majority (93.7%) of the patients were treated by surgery, only one patient (6.2%) of malignant GCT, which was unresectable was treated by radiotherapy.
CONCLUSION
GCT is locally-aggressive tumour. Treatment decision should be made by multidisciplinary team consisting of dedicated experts in field of musculoskeletal oncology and should include radiography, MRI, histopathological assessment and planned surgery supplemented with systemic targeted therapy if indicated.
